-Context -Capecitabine, an oral drug, is as effective as traditional chemotherapy drugs. Objectives -To investigate the adhesion to treatment with oral capecitabine in breast and colorectal cancer, and to determine any correlation with changes in patient's quality of life. Methods -Patients with colorectal cancer or breast cancer using capecitabine were included. The patients were asked to bring any medication left at the time of scheduled visits. The QLQ-C30 questionnaire was applied at the first visit and 8-12 weeks after treatment. Results -Thirty patients were evaluated. Adherence was 88.3% for metastatic colon cancer, 90.4% for non-metastatic colon cancer, 94.3% for rectal cancer and 96.2% for metastatic breast cancer. No strong correlation between adherence and European Organisation for Research and Treatment of Cancer QLQ-C30 functional or symptom scale rates had been found. There was no statistically significant correlation between compliance and the functional and symptom scales of the questionnaire before and after chemotherapy, with the exception of dyspnea. Conclusion -Although no absolute adherence to oral capecitabine treatment had been observed, the level of adherence was good. Health professionals therefore need a greater focus in the monitoring the involvement of patients with oral treatment regimens. Patients with lesser degrees of dyspnea had greater compliance.
BACKGROUND: Colorectal cancer (CRC) is one of the leading causes of cancer worldwide. Early diagnostic methods using serum biomarkers are required. The study of omics, most recently lipidomics, has the purpose of analyzing lipids for a better understanding of human lipidoma. The evolution of mass spectrometry methods, such as MALDI-MS technology, has enabled the detection and identification of a wide variety of lipids with great potential to open new avenues for predictive and preventive medicine. OBJECTIVE: To determine the lipid profile of patients with colorectal cancer and polyps. METHODS: Patients with stage I-III CRC, adenomatous polyps and individuals with normal colonoscopy were selected. All patients underwent peripheral blood collection for lipid extraction. The samples were analyzed by MALDI-MS technique for lipid identification. STATISTICAL ANALYSIS: Univariate and multivariate (principal component analysis [PCA] and discriminant analysis by partial least squares [PLS-DA]) analyses workflows were applied to the dataset, using MetaboAnalyst 3.0 software. The ions were identified according to the class of lipids using the online database Lipid Maps (http://www.lipidmaps.org). RESULTS: We included 88 individuals, 40 with CRC, 12 with polyps and 32 controls. Boxplot analysis showed eight VIP ions in the three groups. Differences were observed between the cancer and control groups, as well as between cancer and polyp, but not between polyps and control. The polyketide (810.1) was the lipid represented in cancer and overrepresented in polyp and control. Among the patients with CRC we observed differences between lipids with lymph node invasion (N1-2) compared to those without lymph node invasion (N). CONCLUSION: Possible lipid biomarkers were identified among cancer patients compared to control and polyp groups. The polyketide lipid (810.1) was the best biomarker to differentiate the cancer group from control and polyp. We found no difference between the biomarkers in the polyp group in relation to the control.
Background: The new tyrosine kinase inhibitors approved for the therapy of non-small cell lung cancer (NSCLC) caused by ALK rearrangement, have been showing an improvement on overall survival, disease progression and toxicity. Method: We performed a retrospective analysis of all the patients with NSCLC and ALK rearrangement that received crizotinib, ceritinib and alectinib as first-line or second-line therapy in our health care unit, by investigating its toxicity and the disease progression. Results: Out of the 113 patients diagnosed with stage IV or stage IIIB lung adenocarcinoma, 17 were ALK positive (from those who had clinical indication and enough histologic material to perform the test). In this population, the mean age was 60,76 years-old and 76,47% (n¼13) were females. Sixteen patients (94,12%) were non-smokers and one (5,88%) was a smoker. By the time of the diagnosis, 94,12% (n¼16) presented with stage IV disease (one of them had brain metastasis and was treated with holocranial radiotherapy) and 5,88% (n¼1) presents with stage IIIB disease. 41,18% (n¼7) had a Performance Status of 0 and 58,82% (n¼10) of 1.Crizotinib was started as first-line therapy in 35,29% (n¼6) of patients and as second-line therapy in 64,71% (n¼11) (these started first with chemotherapy fulfilling either 2, 4 or 6 cycles of treatment). 10 patients showed crizotinib-induced toxicity (1 presented skin rash, 1 presented onicolisis, 6 had liver toxicity and nausea and/or diarrhea, 1 had renal toxicity and 1 presented cardiac toxicity and died). As such, crizotinib dose reduction was needed in 6 patients (4 due to liver toxicity, 1 due to renal toxicity and 1 due to skin rash) and 1 patient had his treatment shifted to ceritinib (because of liver toxicity). Considering follow-up until July 2017, complete and partial response with crizotinib was first seen in 10 and 3 patients, respectively, 3 patients presented disease progression and 1 patient doesn't have follow-up data available yet. After a period of time, 6 patients kept their response to crizotinib and 10 patients showed disease progression (4 patients evolving with cerebral, 2 with bone metastasis, and the remaining with lesions in different locations), and 2 of them eventually died. The average time under crizotinib was 14 month (minimum month and maximum 28 month). 7 of the latter had their treatment shifted to alectinib (n¼ 5) or ceritinib (n¼2). Regarding the data available so far, from the patients that started alectinib 2 showed partial response and 1 showed complete response, and from those under ceritinib 1 showed partial response and 1 showed stability of the disease. From those patients with progression with brain metastasis, 1 is currently under ceritinib (presenting disease stability) and 3 are under alectinib (1 presents complete response, 1 presents partial response, the third doesn't have available follow-up data yet). Three of these patients were treated with holocranial radiotherapy. Conclusion: The experience in our health care unit is similar to the data from ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.